** AbbVie ABBV.N forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug, that is now facing stiff competition
** Median PT of 29 brokerages covering the stock is $205.50 - LSEG data
ROBUST PIPELINE TO FUEL GROWTH
** J.P.Morgan ("overweight") says "more broadly on the story, we see ABBV as well-positioned with no major LOEs (loss of exclusivity) until the mid 2030s, ongoing upside from Skyrizi/Rinvoq, and balance sheet capacity for additional BD to address growth in the 2030s"
** Morgan Stanley ("overweight", PT: $239) says the long-term outlook for its newer immunology drugs, Skyrizi and Rinvoq, continues to bolster confidence in ABBV's long-term growth profile
** Truist Securities ("buy", PT: $217) says "ABBV continues to deliver strong growth into the longer-term and sees no other LOE for the rest of the decade, we see a clear growth trajectory into 2029"
** Morningstar (fair value: $184) says ABBV's transition to more effective immunology products in the face of Humira sales erosion demonstrates its strong competitive advantage
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。